Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Injectable tirzepatide bypasses direct stomach and small intestine exposure, potentially reducing localized GI irritation in some patients
It was first developed in 2012 as a longer-acting option for Liraglutide
For more severe cases, a dermatologist may provide stronger treatment options
Using the Naranjo adverse drug reaction scale, researchers scored the association at 6 out of 13, indicating a "probable" relationship between the medication and the clot
US$ 27.05
US$ 25.93
US$ 28.95
